WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2004007747) ASSAYS FOR ASSEMBLY OF EBOLA VIRUS NUCLEOCAPSIDS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2004/007747    International Application No.:    PCT/US2003/021757
Publication Date: 22.01.2004 International Filing Date: 11.07.2003
IPC:
C12Q 1/18 (2006.01)
Applicants: THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; National Institutes of Health, Office of Technology Transfer, 6011 Executive Blvd., Suite 325, Rockville, MD 20852-3804 (US) (For All Designated States Except US).
NABEL, Gary [US/US]; (US) (For US Only).
HUANG, Yue [CA/US]; (US) (For US Only)
Inventors: NABEL, Gary; (US).
HUANG, Yue; (US)
Agent: DELANEY, Karoline, A.; KNOBBE, MARTENS, OLSON AND BEAR, LLP, 2040 Main Street, Fourteenth Floor, Irvine, CA 92614 (US)
Priority Data:
60/395,876 12.07.2002 US
60/451,317 28.02.2003 US
Title (EN) ASSAYS FOR ASSEMBLY OF EBOLA VIRUS NUCLEOCAPSIDS
(FR) DOSAGES DE REGROUPEMENT DES NUCLEOCAPSIDES DU VIRUS EBOLA
Abstract: front page image
(EN)The present invention relates to assays for the identification of compounds that inhibit assembly of NP, VP35, and VP24, or inhibit the glycosylation of NP, required for nucleocapsid formation, for use as anti-viral agents. The invention also relates to assays for the identification of compounds that block glycosylation of proteins having a glycosylation domain that is substantially homologous to a glycosylation domain of NP required for polymerization. The invention further relates to pseudoparticles for presentation of antigens or antigenic epitopes for immunogenic or vaccination purposes.
(FR)La présente invention concerne des dosages permettant d'identifier des composés inhibant le regroupement de NP, VP35, et de VP24, ou inhibant la glycosylation de NP, nécessaire dans la formation des nucléocapsides, utilisés comme agents antiviraux. L'invention concerne également des dosages permettant d'identifier des composés bloquant la glycosylation de protéines présentant un domaine de glycosylation sensiblement homologue à un domaine de glycosylation de NP nécessaire pour la polymérisation. L'invention concerne, de plus, des pseudoparticules de présentation des antigènes ou épitopes antigéniques à des fins immunogéniques ou de vaccination.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)